LIPF
ENSG00000182333
Target class
Enzyme
Chromosome
10
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- LIPF
- Gene name
- Lipase F, gastric type
- Gene symbol
- LIPF
- Protein name
- Gastric triacylglycerol lipase (GL) (Gastric lipase) (EC 3.1.1.3)
- HGL
- HLAL
- Gene biotype
- Protein coding
- Gene family
- Lipases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 23
- Highest tissue expression
- 28,812.8
- Tissue specificity (Gini)
- 0.981
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:8513
- Reactome pathways
- R-HSA-192456
- Protein interaction confidence
- 0.876474
- Protein interaction partners
- 19
- End position
- 88678814
- Start position
- 88664441
- Chromosome
- 10
- Strand
- Forward
- Secreted .
- Tissue specificity (tau)
- 0.999961
- Expression inequality (Gini)
- 0.980501
Expression in transcripts per million
- Stomach
- 28,812.8
- Cervix - Ectocervix
- 4.98
- Testis
- 4.33
- Fallopian Tube
- 4.12
- Pituitary
- 3.72
Expression in transcripts per million
- Stomach28,812.8
- Cervix - Ectocervix4.98
- Testis4.33
- Fallopian Tube4.12
- Pituitary3.72
- Bladder2.91
- Cervix - Endocervix2.49
- Spleen2.46
- Uterus2.19
- Esophagus - Mucosa2.07
- Ovary2.04
- Small Intestine - Terminal Ileum1.79
- Brain - Cerebellum1.76
- Adrenal Gland1.75
- Pancreas1.72
- Vagina1.68
- Liver1.66
- Kidney - Medulla1.64
- Prostate1.5
- Colon - Transverse1.33
- Esophagus - Gastroesophageal Junction1.21
- Thyroid1.2
- Minor Salivary Gland1.05
- Esophagus - Muscularis0.95
- Artery - Aorta0.9
And 29 more, listed on the interactive page.
- GO:0004806
- GO:0005515
Related records
Trials (65)
- A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
- A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
- A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
- A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
- A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
- A Trial With EMP16 in Preparation for Late Phase Studies
- Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
- Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
- An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
- Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)
- Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
- Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
- Comparison of MAG and Fish Oil Efficacy
- Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
- Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
- Effect of Orlistat in Body Composition
- Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial
Drugs (2)
- Cetilistat Gastric lipase inhibitor
- Orlistat Gastric lipase inhibitor